Literature DB >> 11745060

Aortic valve replacement with a stentless bioprosthesis using the full-root technique.

O Wendler1, V Dzindzibadze, F Langer, S El Dsoki, H J Schäfers.   

Abstract

BACKGROUND: In aortic valve replacement stentless bioprostheses results in improved hemodynamic function compared to stented valves. Using the root replacement technique even larger prostheses are implantable. We present our experience with stentless bioprostheses implanted in the "full-root" technique. PATIENTS AND METHODS: Between 01/1997 and 12/2000, 149 patients underwent root replacement with a stentless xenograft (age 70 +/- 9y, women 52 %, ejection-fraction 58 +/- 15 %). Isolated stenosis was present in 34 %, incompetence in 24 %, and mixed disease in 42 % of patients. Bacterial endocarditis was found in 16 %, and 3 patients suffered from acute aortic dissection.
RESULTS: Mean bypass time was 118 +/- 45 min, ischemic time 83 +/- 26 min and operating time 201 +/- 62 min. Concomitant procedures were CABG (32 %), replacement of ascending aorta (22 %) and aortic arch (13 %), mitral valve repair (6.7 %), and carotid thrombendarterectomy (1.3 %). Total in-hospital mortality was 6.7 %, with a 1.8 % mortality rate for patients with isolated aortic valve disease.
CONCLUSION: Aortic valve replacement using stentless bioprostheses in the root replacement technique is a safe surgical option. In patients with small aortic roots or ring abscesses it guarantees remodelling of the aortic annulus.

Entities:  

Mesh:

Year:  2001        PMID: 11745060     DOI: 10.1055/s-2001-19014

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  1 in total

1.  Full-root aortic valve replacement with stentless xenograft achieves superior regression of left ventricular hypertrophy compared to pericardial stented aortic valves.

Authors:  Reza Tavakoli; Christoph Auf der Maur; Xavier Mueller; Reinhard Schläpfer; Peiman Jamshidi; François Daubeuf; Nelly Frossard
Journal:  J Cardiothorac Surg       Date:  2015-02-03       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.